Last reviewed · How we verify
AC2993
AC2993 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.
AC2993 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss. Used for Type 2 diabetes mellitus, Obesity or weight management.
At a glance
| Generic name | AC2993 |
|---|---|
| Also known as | synthetic exendin-4, Exenatide |
| Sponsor | AstraZeneca |
| Drug class | Dual GLP-1/GIP receptor agonist |
| Target | GLP-1R, GIPR |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
By simultaneously stimulating GLP-1 and GIP receptors, AC2993 enhances insulin secretion in response to glucose, slows gastric emptying, and increases satiety signaling in the brain. This dual mechanism produces greater reductions in blood glucose and body weight compared to GLP-1 monotherapy, making it potentially more effective for type 2 diabetes and obesity management.
Approved indications
- Type 2 diabetes mellitus
- Obesity or weight management
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Gastrointestinal disorders
Key clinical trials
- Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis (PHASE2)
- Exenatide for Smoking Cessation and Prevention of Weight Gain (PHASE2)
- A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
- Exenatide For Reducing the Reinforcing Effects of Cocaine (PHASE1)
- GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) (PHASE2)
- Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome (PHASE3)
- Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study) (PHASE4)
- A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AC2993 CI brief — competitive landscape report
- AC2993 updates RSS · CI watch RSS
- AstraZeneca portfolio CI